Skip to Main Content

Come Friday morning, Amgen will reveal whether its costly, much-discussed new cholesterol drug will live up to blockbuster expectations — or become a cautionary tale in biopharma lore.

At the American Cardiology Conference in Washington, D.C., Amgen will present results from a 27,000-patient study determining whether its drug can reduce patients’ risk of heart attack and stroke, with sweeping ramifications for payers, patients, investors, and pharma.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • My cholesterol in September of 2016 was 240 and my LDL was 167 and here in March of 2017 after only 3 injections of Praluent 75 mg. My cholesterol is now 114 and my LDL is 37. Pretty amazing

Comments are closed.